Rotavirus vaccines: considerations for successful implementation in Europe

Pierre Van Damme; Marie Van der Wielen; Filippo Ansaldi; Daniel Desgrandchamps; Javier Diez Domingo; Francisco Gimenez Sanchez; James Gray; Martin Haditsch; Kari Johansen; Paula Lorgelly; Mathie Lorrot; Nathalie Parez; Volkmar Reschke; Markus Rose

doi:10.1016/S1473-3099(06)70657-0

Rotavirus vaccines: considerations for successful implementation in Europe

Pierre Van Damme^*, Marie Van der Wielen, Filippo Ansaldi, Daniel Desgrandchamps, Javier Diez Domingo, Francisco Gimenez Sanchez, James Gray, Martin Haditsch, Kari Johansen, Paula Lorgelly, Mathie Lorrot, Nathalie Parez, Volkmar Reschke, Markus Rose

^*Corresponding author for this work

Research output: Contribution to journal › Comment/debate

38 Citations (Scopus)

Abstract

A group of European experts in infectious diseases and vaccinology has met on several occasions to assess the rationale for universal vaccination against rotavirus infection of infants in Europe. On the basis of the available data, we concluded that vaccination was the best approach to prevent severe rotavirus gastroenteritis, and that European countries should consider implementing rotavirus vaccination in their routine immunisation programmes. The main barrier to the implementation of rotavirus vaccination in Europe is a general lack of awareness of stakeholders, policymakers, health-care professionals, and parents about rotavirus disease and the advantages of vaccination. Further studies on the cost of the disease and the benefit of vaccination, together with raising awareness are necessary steps to ensure successful implementation of rotavirus vaccination in Europe.

Original language	English
Pages (from-to)	805-812
Number of pages	8
Journal	Lancet Infectious Diseases
Volume	6
Issue number	12
DOIs	https://doi.org/10.1016/S1473-3099(06)70657-0
Publication status	Published - Dec 2006

Bibliographical note

Funding Information:
PVD was a principal investigator of vaccine trials for Merck, Sanofi Pasteur-MSD (SP-MSD), and GlaxoSmithKline Biologicals for which the university of Antwerp receives research grants. FA is a co-experimenter for an epidemiological study supported by a grant from Sanofi Pasteur. DD has received several unrestricted educational grants from SP-MSD Europe and SP-MSD Switzerland. JDD is principal investigator of vaccine trials and/or epidemiological studies for Merck, SP-MSD, and GlaxoSmithKline Biologicals for which the Vaccine Institute of Valencia receives research grants. He also addresses conferences for SP-MSD and GlaxoSmithKline. KJ has received research grants from GlaxoSmithKline and Sanofi Pasteur, and reports that her participation in advisory board meetings was covered by SP-MSD. NP has received honoraria from GlaxoSmithKline and SP-MSD. RM has received honoraria for lectures and attendance at paediatric advisory boards from SP-MSD and GlaxoSmithKline. MVW, FGS, JG, MH, PL, ML, and VR declare that they have no conflicts of interest.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S1473-3099(06)70657-0

Cite this

Van Damme, P., Van der Wielen, M., Ansaldi, F., Desgrandchamps, D., Domingo, J. D., Sanchez, F. G., Gray, J., Haditsch, M., Johansen, K., Lorgelly, P., Lorrot, M., Parez, N., Reschke, V., & Rose, M. (2006). Rotavirus vaccines: considerations for successful implementation in Europe. Lancet Infectious Diseases, 6(12), 805-812. https://doi.org/10.1016/S1473-3099(06)70657-0

@article{d8e03c2ca0204cc2bba3dbba5043c97d,

title = "Rotavirus vaccines: considerations for successful implementation in Europe",

abstract = "A group of European experts in infectious diseases and vaccinology has met on several occasions to assess the rationale for universal vaccination against rotavirus infection of infants in Europe. On the basis of the available data, we concluded that vaccination was the best approach to prevent severe rotavirus gastroenteritis, and that European countries should consider implementing rotavirus vaccination in their routine immunisation programmes. The main barrier to the implementation of rotavirus vaccination in Europe is a general lack of awareness of stakeholders, policymakers, health-care professionals, and parents about rotavirus disease and the advantages of vaccination. Further studies on the cost of the disease and the benefit of vaccination, together with raising awareness are necessary steps to ensure successful implementation of rotavirus vaccination in Europe.",

author = "{Van Damme}, Pierre and {Van der Wielen}, Marie and Filippo Ansaldi and Daniel Desgrandchamps and Domingo, {Javier Diez} and Sanchez, {Francisco Gimenez} and James Gray and Martin Haditsch and Kari Johansen and Paula Lorgelly and Mathie Lorrot and Nathalie Parez and Volkmar Reschke and Markus Rose",

note = "Funding Information: PVD was a principal investigator of vaccine trials for Merck, Sanofi Pasteur-MSD (SP-MSD), and GlaxoSmithKline Biologicals for which the university of Antwerp receives research grants. FA is a co-experimenter for an epidemiological study supported by a grant from Sanofi Pasteur. DD has received several unrestricted educational grants from SP-MSD Europe and SP-MSD Switzerland. JDD is principal investigator of vaccine trials and/or epidemiological studies for Merck, SP-MSD, and GlaxoSmithKline Biologicals for which the Vaccine Institute of Valencia receives research grants. He also addresses conferences for SP-MSD and GlaxoSmithKline. KJ has received research grants from GlaxoSmithKline and Sanofi Pasteur, and reports that her participation in advisory board meetings was covered by SP-MSD. NP has received honoraria from GlaxoSmithKline and SP-MSD. RM has received honoraria for lectures and attendance at paediatric advisory boards from SP-MSD and GlaxoSmithKline. MVW, FGS, JG, MH, PL, ML, and VR declare that they have no conflicts of interest. ",

year = "2006",

month = dec,

doi = "10.1016/S1473-3099(06)70657-0",

language = "English",

volume = "6",

pages = "805--812",

journal = "Lancet Infectious Diseases",

issn = "1473-3099",

publisher = "Elsevier Ltd.",

number = "12",

}

TY - JOUR

T1 - Rotavirus vaccines

T2 - considerations for successful implementation in Europe

AU - Van Damme, Pierre

AU - Van der Wielen, Marie

AU - Ansaldi, Filippo

AU - Desgrandchamps, Daniel

AU - Domingo, Javier Diez

AU - Sanchez, Francisco Gimenez

AU - Gray, James

AU - Haditsch, Martin

AU - Johansen, Kari

AU - Lorgelly, Paula

AU - Lorrot, Mathie

AU - Parez, Nathalie

AU - Reschke, Volkmar

AU - Rose, Markus

N1 - Funding Information: PVD was a principal investigator of vaccine trials for Merck, Sanofi Pasteur-MSD (SP-MSD), and GlaxoSmithKline Biologicals for which the university of Antwerp receives research grants. FA is a co-experimenter for an epidemiological study supported by a grant from Sanofi Pasteur. DD has received several unrestricted educational grants from SP-MSD Europe and SP-MSD Switzerland. JDD is principal investigator of vaccine trials and/or epidemiological studies for Merck, SP-MSD, and GlaxoSmithKline Biologicals for which the Vaccine Institute of Valencia receives research grants. He also addresses conferences for SP-MSD and GlaxoSmithKline. KJ has received research grants from GlaxoSmithKline and Sanofi Pasteur, and reports that her participation in advisory board meetings was covered by SP-MSD. NP has received honoraria from GlaxoSmithKline and SP-MSD. RM has received honoraria for lectures and attendance at paediatric advisory boards from SP-MSD and GlaxoSmithKline. MVW, FGS, JG, MH, PL, ML, and VR declare that they have no conflicts of interest.

PY - 2006/12

Y1 - 2006/12

N2 - A group of European experts in infectious diseases and vaccinology has met on several occasions to assess the rationale for universal vaccination against rotavirus infection of infants in Europe. On the basis of the available data, we concluded that vaccination was the best approach to prevent severe rotavirus gastroenteritis, and that European countries should consider implementing rotavirus vaccination in their routine immunisation programmes. The main barrier to the implementation of rotavirus vaccination in Europe is a general lack of awareness of stakeholders, policymakers, health-care professionals, and parents about rotavirus disease and the advantages of vaccination. Further studies on the cost of the disease and the benefit of vaccination, together with raising awareness are necessary steps to ensure successful implementation of rotavirus vaccination in Europe.

AB - A group of European experts in infectious diseases and vaccinology has met on several occasions to assess the rationale for universal vaccination against rotavirus infection of infants in Europe. On the basis of the available data, we concluded that vaccination was the best approach to prevent severe rotavirus gastroenteritis, and that European countries should consider implementing rotavirus vaccination in their routine immunisation programmes. The main barrier to the implementation of rotavirus vaccination in Europe is a general lack of awareness of stakeholders, policymakers, health-care professionals, and parents about rotavirus disease and the advantages of vaccination. Further studies on the cost of the disease and the benefit of vaccination, together with raising awareness are necessary steps to ensure successful implementation of rotavirus vaccination in Europe.

UR - http://www.scopus.com/inward/record.url?scp=33845489787&partnerID=8YFLogxK

U2 - 10.1016/S1473-3099(06)70657-0

DO - 10.1016/S1473-3099(06)70657-0

M3 - Comment/debate

C2 - 17123900

AN - SCOPUS:33845489787

SN - 1473-3099

VL - 6

SP - 805

EP - 812

JO - Lancet Infectious Diseases

JF - Lancet Infectious Diseases

IS - 12

ER -

Rotavirus vaccines: considerations for successful implementation in Europe

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this